Categories: News

CAS SciFinder integrates transformative new science-smart AI capabilities to enhance R&D efficiency and boost innovation

Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery

- Advertisement -

COLUMBUS, Ohio, Aug. 4, 2025 /PRNewswire/ — CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the launch of the next evolution of CAS SciFinder®, the leading scientific search and insights platform. By integrating advanced AI—optimized for scientific applications—with the largest human-curated collection of global scientific knowledge, CAS SciFinder empowers researchers across R&D to work faster and unlock new opportunities for innovation.

- Advertisement -

This marks the most significant integration of AI within the CAS solution portfolio to date. “Scientific information is diverse and complex, making it challenging for common AI tools to interpret accurately,” noted Tim Wahlberg, CAS Chief Product Officer. “Applying these technologies to the high-quality, structured data in the CAS Content Collection™ and engaging our team of scientists to verify the advanced AI models enabled us to develop a science-smart AI approach that delivers accurate and reliable answers scientists can trust.”

- Advertisement -

SearchSense, a collection of new AI-driven search capabilities in CAS SciFinder, was developed to make scientific information more accessible across R&D workflows and help researchers reach actionable answers faster. With a single search box, users can initiate a broad range of inquiries by asking simple questions using natural language. AI-enabled summaries help users quickly interpret results and pinpoint the most relevant information to provide a clear answer they trust. Ninety-three percent of beta testers agree that the new search features in CAS SciFinder make them more efficient. The platform also learns from user activity to personalize results and streamline future searches. To ensure the security of all user queries, results, and interactions in CAS SciFinder, AI features operate within a closed system.

- Advertisement -

CAS also continues to lead innovation in retrosynthesis with the introduction of the first real-time, interactive synthetic planning tool. This is a paradigm shift for chemists that slashes the time needed to generate a synthetic plan from minutes to just a few seconds. By eliminating wait times and providing real-world evidence directly in synthetic maps for quick comparison, Interactive Retrosynthesis in CAS SciFinder significantly increases efficiency and enables greater creativity in reaction planning and optimization. Scientist-enhanced AI is also being leveraged for more accurate interpretation of users’ reaction queries to deliver unmatched search accuracy and precision within the largest collection of curated reaction information.

- Advertisement -

To address a growing need among scientists and stakeholders in all phases of R&D to have greater visibility of the intellectual property (IP) landscape, additional IP search support, visualization capabilities, and patent details have also been added to CAS SciFinder. Users can now easily identify prior art within their typical workflow with the help of IP Connections. This CAS-developed AI algorithm matches relevant patent and non-patent publications from any free-text input to inform more confident prioritization and reduce the risk of wasted time and investment.

- Advertisement -

“The process of scientific discovery is constantly evolving, and we are committed to advancing our solutions with the latest technology to provide the best insights, most efficient workflow, and an optimal user experience to meet our customers’ changing needs,” said Manuel Guzman, President of CAS. “With so many scientists around the globe relying on CAS SciFinder, these new capabilities meaningfully impact the speed of discovery and ultimately help deliver life-changing innovations faster.

- Advertisement -

Visit the CAS SciFinder preview site to learn more about the new features, which will be deployed to users in phases over the next two months.

- Advertisement -

About CAS

- Advertisement -

CAS connects the world’s scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today’s complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. Connect with us at cas.org. CAS is a division of the American Chemical Society.

- Advertisement -

Logo – https://mma.prnewswire.com/media/1729161/CAS_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/cas-scifinder-integrates-transformative-new-science-smart-ai-capabilities-to-enhance-rd-efficiency-and-boost-innovation-302519937.html

- Advertisement -

Recent Posts

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

55 minutes ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

2 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

2 hours ago

New TALVEY(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of…

2 hours ago

President Droupadi Murmu Confers Kirti Chakra on Chandigarh University Alumnus Major Arshdeep Singh Gill

"Chandigarh University not only provides quality education but also instills a spirit of patriotism," says…

4 hours ago

Bitmine Immersion Technologies Announces Initial Dividends and NYSE Listing for Series A Preferred Stock

Bitmine's Board of Directors declares initial cash dividends on the Company's 9.50% Series A Perpetual…

6 hours ago